What We're Reading: Page 168
Industry reads hand-picked by our editors
Feb 16, 2021
Feb 12, 2021
-
Nature
This COVID-vaccine designer is tackling vaccine hesitancy — in churches and on Twitter
-
STAT
Amicus drug for Pompe disease falls short in key clinical trial
-
Endpoints News
All in on ide-cel, Bristol Myers Squibb writes off $470M as second BCMA CAR-T is ejected from the pipeline
-
The Washington Post
Drug companies seek billion-dollar tax deductions from opioid settlement
Feb 11, 2021
-
The New York Times
‘A Game Changer’: Drug Brings Weight Loss in Patients With Obesity
-
Reuters
Merck in talks with governments, other drugmakers to produce COVID-19 shots
-
The Wall Street Journal
Eli Lilly Doesn’t Plan to Claw Back Past Pay From Former CFO
-
Evaluate Vantage
2020 wins top of the froths for biotech stocks
Feb 10, 2021
-
The Wall Street Journal
SoftBank to Make $900 Million Investment in Pacific Biosciences
-
C&EN
The race to repurpose nature's protein factories
-
The New York Times
Could a Single Vaccine Work Against All Coronaviruses?
-
Endpoints News
With 'rapid' progress of pediatric brain cancer treatment, Day One sees broad excitement in new crossover round
Feb 09, 2021
-
The New York Times
A Few Covid Vaccine Recipients Developed a Rare Blood Disorder
-
STAT
Woodcock vs. Sharfstein: A head-to-head comparison of Biden’s top choices for FDA commissioner
-
The Financial Times
Hong Kong biotech sector booms on buoyant markets and pandemic
-
The Wall Street Journal
What to Do When There’s a Covid-19 Vaccine Glut
Feb 08, 2021
-
STAT
How a journal's censure inflamed debate over Biogen's Alzheimer's drug
-
Vogue
Science Not Politics: How Dr. Rochelle Walensky is Saving the CDC
-
Financial Times
How AstraZeneca’s vaccine was hit by flawed trials, defects and politics — but might still save the world
-
Endpoints News
‘Can’t say no’: Kite Therapeutics taps Frank Neumann as new head of clinical development
Feb 05, 2021
-
POLITICO
Biden health team hatches new vaccine strategy as variant threat builds
-
The Wall Street Journal
Merck CFO Brings Corporate Strategy Experience to CEO Role
-
FiercePharma
Roche hit by worst-case biosim assault — to the tune of $5.6B — as COVID-19 hurts Ocrevus
-
BioSpace
FDA Approves Merck KGaA's Tepmetko for Aggressive Lung Cancer
Previous
